This study aimed to investigate the effect of denosumab on bone mineral density(BMD), bone turnover markers(BTMs), functional status, secondary fracture rate, and adverse effects in osteoporotic vertebral compression fracture (OVCF) patients after vertebroplasty during a 12-month follow-up period.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Procollagen type 1 n-terminal propeptide (P1NP)
Timeframe: up to 12 months
C-terminal cross-linked type 1 collagen terminal peptide (CTX)
Timeframe: up to 12 months
Lumbar bone mineral density(BMD)
Timeframe: up to 12 months
Total hip BMD
Timeframe: up to 12 months
Femoral neck BMD
Timeframe: up to 12 months
Visual analog scale (VAS) back
Timeframe: up to 12 months